VBWG In-hospital course of stroke patients with vs without AF Steger C et al. Eur Heart J. 2004;6:in press. More severe stroke on admission Lower Barthel.

Slides:

Advertisements

Similar presentations

Screening and diagnosis of AF and stratifying stroke risk.

Advertisements

Prosthetic Valve; Anticoagulation After ICH Dr.Tahsin.N.

Concomitant Antiplatelet and OAC Tx: Real-World Practice In the US, ~800,000 AF patients are on concomitant OAC and antiplatelet tx 1 Patients on chronic.

Update on Anti-platelets Gabriel A. Vidal, MD Vascular Neurology Ochsner Medical Center October 14 th, 2009.

Emily O’Brien, MSPH Predoctoral Trainee February 16, 2010 The North Carolina Stroke Care Collaborative Clinical Outcomes among Stroke Patients Receiving.

“Influence of Stroke Subtype on Quality of Care in The Get With The Guidelines-Stroke Program” Eric E. Smith, MD, MPH; Li Liang PhD; Adrian F Hernandez,

Canadian Diabetes Association Clinical Practice Guidelines Acute Coronary Syndromes and Diabetes Chapter 26 Jean-Claude Tardif, Phillipe L. L’Allier, David.

Atrial Fibrillation in Patients with Cryptogenic Stroke Gladstone DJ et al. N Engl J Med 2014; 370: Presented by Kris Huston | July 21, 2014.

Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.

Peking University Dayi Hu Sept 16, IHF,Beijing, 2005 Atrial Fibrillation in China.

“ Age-Related Differences in Characteristics, Performance Measures, Treatment Trends, and Outcomes in Patients with Ischemic Stroke ” Gregg C. Fonarow,

TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators.

Treating Atrial Fibrillation Richard Schilling St Bartholomew's Hospital, Queen Mary’s University of London.

Surveillance of Heart Diseases and Stroke Using Centers for Medicare and Medicaid (CMS) Data: A Researcher’s Perspective Judith H. Lichtman, PhD MPH Associate.

Jim Hoehns, Pharm.D.. Edoxaban Oral factor Xa inhibitor Bioavailability: 62% Tmax: 1-2 hrs Elimination: 50% renal Half-life: 9-11 hours.

Update on the Medical Management of Acute Coronary Syndrome.

Atrial Fibrillation Warfarin and its newer alternatives

Warfarin Dabigatran Rivaroxaban Apixaban Edoxaban Target

Coronary Artery Disease Angina Pectoris Unstable Angina Variant Angina Joseph D. Lynch, MD.

VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.

Management of Hypertensive Emergencies. New paradigm in treatment of acute hypertension Acute vascular injury has chronic sequelae Prevention of exaggerated.

Oral Rivaroxaban for Symptomatic Venous Thrombroenbolism Group /06/11.

Acute Stroke: Principles of Modern Management A program of the American Academy of Neurology The AAN Acute Stroke Management courses are supported in part.

Hyperglycemia and Acute Coronary Syndromes. Cardiovascular disease and diabetes Bell DSH. Diabetes Care. 2003;26: Centers for Disease Control.

Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients With Nonvalvular Atrial Fibrillation SPORTIF V Trial Presented at American.

ARISTOTLE Objectives Primary: test for noninferiority of apixaban, a novel oral direct factor Xa inhibitor, versus warfarin Secondary: test for superiority.

The Renin-Angiotensin- Aldosterone System: Linking New Data and Mechanisms for Cardiovascular Risk Reduction VBWG.

Oral Rivaroxaban for Symptomatic Venous Thromboembolism.

Heart failure: The national burden AHA. Heart disease and stroke statistics–2005 update. Koelling TM et al. Am Heart J. 2004;147:74-8. VBWG Affects 1 million.

A Randomized Trial of Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism Schulman S et al. Proc ASH 2011;Abstract 205.

Update from the AHA 2010 Jonathan Silberberg February 2011.

Can Nurses Assist Older CHF Patients With Self-Care? Sallie A. Alvarez NGR 5800 American Heart Association.

A-4 Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Pierre Jais Atrial Fibrillation Ablation vs. Antiarrhythmic Drugs Trial.

Long-term mortality and thrombolysis therapy after a first acute ischemic stroke: gender differences. Ebrictus II Study. Authors & Affiliations Clua-Espuny.

VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.

Rhythm and Rate Control for Atrial Fibrillation Tom Wallace, MD Cardiac Electrophysiology CHI St. Vincent Heart Clinic Arkansas.

The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.

Palpitations & Atrial Fibrillation Dr Mehul B Dhinoja, Consultant Cardiologist & Electrophysiologist BMI The London Independent Hospital.

以多重死因資料比較台灣美國腦中風併發吸入性肺炎之趨勢奇美醫學中心張嘉祐醫師. Stroke Statistics -- A Report From the American Heart Association Approximately 56% of stroke deaths in 2009.

Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical Practice.

Stoke On Trent CCG – Atrial Fibrillation Service AF Nurse in GP Practice Interfacing Primary and Secondary Care for AF Stroke Prevention Jodie Williams.

Stoke On Trent CCG – Atrial Fibrillation Service AF Nurse in GP Practice Interfacing Primary and Secondary Care for AF Stroke Prevention Jodie Williams.

ResultsIntroduction Atrial Fibrillation (AF) affects 1.2% 1 of the population and 10% of those over the age of 75 2 It is the commonest arrhythmia in primary.

N Engl J Med 2009;361: Stuart J. Connolly, M.D., Michael D. Ezekowitz, M.B., Ch.B., D.Phil., Salim Yusuf, F.R.C.P.C., D.Phil., John Eikelboom,

Stroke i Finnmark, Norge 1998 Riskfaktorer, Klinisk bild, Ettårsuppföljning av förstagångsattacker Fjernundervisning 30. April 2002 Sven-Mårten Samuelsson,

Cost effectiveness of AF monitoring strategies in a post-stroke population LAUREN E. CIPRIANO JEFF HEALEY OMAR AKHTAR KAREN LEE LUCIANO A. SPOSATO APRIL.

R2. 최태웅 / Pf. 김진배. BACKGROUND  Ischemic stroke : leading causes of death and disability : cause remains unexplained after routine evaluation → Cryptogenic.

Review on NOACs Studies DR. KOUROSH SADEGHI TEHRAN UNIVERSITY OF MEDICAL SCIENCES.

Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart DiseaseClinical Perspective by Michael D. Ezekowitz, Rangadham.

Hypertension In The Stroke Patient

Epidemiology and burden of atrial fibrillation and associated stroke

Evaluation of the Efficacy and Safety of Direct Oral Anticoagulants in Japanese Patients—Analysis of Pharmaceuticals and Medical Devices Agency Data

Heart Valve Thrombosis & Neuro-Outcomes

A Comparison of RE-LY and ROCKET AF Trial Designs and Outcomes

Screening and diagnosis of AF and stratifying stroke risk

Clinical need for determination of vulnerable plaques

Quality of Referrals Guideline Congruence of referrals to TIAMS clinic

Atrial fibrillation and stroke: Disease awareness

Anticoagulation in Atrial Fibrillation

Silent No More:.

Oral Anticoagulation and Preventing Stent Thrombosis

Setareh Omran, MD Vascular Neurology Fellow

Overall burden of AF associated with higher risk of thromboembolism and ischemic stroke An analysis of the KP-RHYTHM study, in patients with paroxysmal.

A. Heart failure: A challenge to the healthcare delivery system

NOACS: Emerging data in ACS/IHD

A. Epidemiology update:

Taking the "Cryptogenic" Out of Cryptogenic Stroke

Taking the "Cryptogenic" Out of Cryptogenic Stroke

Overall burden of AF associated with higher risk of thromboembolism and ischemic stroke An analysis of the KP-RHYTHM study, in patients with paroxysmal.

The CHA(2)DS2-(VASc) stroke risk and HAS-BLED bleeding risk index are calculated by totalling the scores for each risk factor present.68–71 The lower graph.

Presentation transcript:

VBWG In-hospital course of stroke patients with vs without AF Steger C et al. Eur Heart J. 2004;6:in press. More severe stroke on admission Lower Barthel Index Higher proportion with Rankin Scale score (%) Higher rate of medical complications Pneumonia (%) Pulmonary edema (%) Symptomatic intracerebral hemorrhage (%) Mortality (%) Poorer neurological status at discharge Lower Barthel Index Higher Rankin Scale score P < for all comparisons With AFWithout AF

VBWG Detection of AF after acute stroke/TIA Jabaudon D et al. Stroke. 2004;35: ELR = 2-lead event-loop recording device N = 149Stroke/TIA ECG No Yes 4 (2.7%) 6 (4.1%) 7 (4.9%) 5 (5.7%) n = 88/132 7-day ELR n = 145 Additional ECG n = hr Holter No Yes AF? No. AF detected Yes AF? No AF?

VBWG Risk of AF by duration of heart rhythm Jabaudon D et al. Stroke. 2004;35: Monitoring time (hours) AF risk (%) ECG HolterELR

VBWG Recurrence of AF 13 months post-stroke/TIA Jabaudon D et al. Stroke. 2004;35: ELR = 2-lead event-loop recording device ECG or 24-hr Holter7-day ELR AF recurrence (%)

VBWG Clinical challenge: Addressing the rising burden of AF and stroke Lloyd-Jones DM et al. Circulation. 2004;110: AHA. Heart Disease and Stroke Statistics—2004 Update. Jabaudon D et al. Stroke. 2004;35: AF continues to present an enormous public health problem – Men and women >40 yrs have lifetime risk for AF of ~1 in 4 – Estimated 2.2 million Americans – May account for up to 140,000 strokes yearly ECG and 24-hr Holter monitoring do not identify all stroke/TIA patients with AF Many AF patients are not receiving anticoagulant therapy to prevent recurrent stroke

VBWG Role of anticoagulant therapy in secondary prevention of stroke AF should be strongly suspected in all patients with acute stroke/TIA or TIA – All stroke/TIA patients with confirmed AF should receive anticoagulant therapy Warfarin – Pro: Proven effective – Con: Need for frequent (and costly) monitoring and dose adjustment New anticoagulants that offer fixed dosing with no monitoring are under investigation and may address warfarin’s shortcomings – Oral (direct thrombin inhibitors, ie, ximelagatran) – Parenteral (low–molecular-weight heparins, factor Xa inhibitors)